|
gptkbp:instanceOf
|
gptkb:drug
alpha-2 adrenergic agonist
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N05CM18
|
|
gptkbp:bioavailability
|
16% (oral)
|
|
gptkbp:brand
|
gptkb:Precedex
|
|
gptkbp:CASNumber
|
113775-47-6
|
|
gptkbp:category
|
analgesic
benzodiazepine
sedative
sympatholytic
|
|
gptkbp:contraindication
|
advanced heart block
severe ventricular dysfunction
|
|
gptkbp:discoveredBy
|
gptkb:Orion_Pharma
|
|
gptkbp:effect
|
minimal respiratory depression
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C13H16N2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dexmedetomidine
|
|
gptkbp:interactsWith
|
opioids
antihypertensives
other sedatives
anesthetics
|
|
gptkbp:IUPACName
|
gptkb:(S)-4-(1H-imidazol-4-yl)benzyl-1,2-dimethylbenzene
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
alpha-2 adrenergic receptor agonism
|
|
gptkbp:meltingPoint
|
112-114°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
94%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201313
5311068
|
|
gptkbp:relatedTo
|
gptkb:medetomidine
|
|
gptkbp:routeOfAdministration
|
intravenous
intranasal
|
|
gptkbp:sideEffect
|
nausea
hypotension
dry mouth
bradycardia
hypertension (transient)
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
UYX8H8BQH7
|
|
gptkbp:usedFor
|
sedation
analgesia
anxiolysis
|
|
gptkbp:usedIn
|
intensive care unit
procedural sedation
|
|
gptkbp:bfsParent
|
gptkb:Precedex
|
|
gptkbp:bfsLayer
|
6
|